Objective
To summarise a conference convened to examine how cystic fibrosis screening might appropriately be introduced into routine prenatal practice.
Methods
Participants included experts from various relevant disciplines. Systematic reviews and data from individual trials were presented; issues were identified and discussed.
Results
Judged by published criteria, prenatal cystic fibrosis screening is suitable for introduction. Screening can be performed cost effectively by identifying racial/ethnic groups at sufficient risk and then using either of two models for delivering laboratory services. Validated educational materials exist. Ethical issues are not unique.
Conclusions
Once adequate facilities for patient and provider education, testing, counselling, quality control, and monitoring are in place, individual programmes can begin prenatal screening for cystic fibrosis.
